Forty Seven jumps 23% after Bloomberg report of Gilead approach

Forty Seven (FTSV), a clinical-stage immuno-oncology company, is higher by over 23% in after-hours trading following a report by Bloomberg's Ed Hammond and Nabila Ahmed that Gilead Sciences (GILD) has approached the company with a takeover offer, and that the companies have also discussed other options, including a partnership. The report also added that Forty Seven has "received interest from other potential suitors as well," citing their source. In after-hours trading, Forty Seven is up 23.4% to $60.20, while Gilead is higher by 1.5% to $73.76.